IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kai SCHIEMANN

Serial No.: 10/551,998			Group Art Unit: 1626		
Filed: October 5, 2006 Exa			Examiner: Yong Liang Chu		
For:	1,3,4-SUBSTITUTED PYRAZOLES AS 5-HT RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS				
INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98					
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
Sir:					
This information disclosure statement is made in accordance with 37 C.F.R. $\$\$$ 1.56, 1.97 and 1.98 as follows:					
Timing and Fees					
	Under 37 C.F.R. \S 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:				
		within three months of the filing date of a natunder § 1.53(d);	tional application other than a CPA		
		within three months of the actual filing da application; OR	te of the national phase of a PCT		
		before the mailing of a first substantive office RCE).	e action (including after filing of an		
	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods specified in 37 C.F.R. § 1.97(b), but before the mailing date of:				

termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

a final rejection under 37 C.F.R. 1.113;

			the statement as specified in 37 C.F.R. § 1.97(e) set out below;		
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or		
			payment by credit card via EFS covering the fee of \$180.00 under 37 C.F.R. \S 1.17(p).		
		r 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing of the following actions which have not been withdrawn:			
		a final	action under 37 C.F.R. § 1.113;		
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);		
		OR a	notice of allowance under 37 C.F.R. § 1.311;		
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:		
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).		
Staten	nents U	nder 37	C.F.R. 1.97(e)		
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or		
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.		
Cited Materials					
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).		
	\boxtimes	Copie	s of Non Final and Final Rejections listed in other U.S. applications or		

is accompanied by:

patents are not attached. Applicants request that the Examiner obtain them

	Applicants will supply them as a supplement.			
\boxtimes	Not required by 37 CFR § 1.98.			
\boxtimes	Copies of the materials listed are attached (except for the foregoing).			
Non-Engl	ish Language References			
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).			
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:			
	X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document			
	A = document defining the general state of the art O = non-written disclosure			
	P = intercalated document			
	T = document cited to understand the theory or principle underlying the invention			
	E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date			
	D = cited in the application			
	L = cited for another reason			
	& = publication of member of same patent family			
	☐ Translation of other relevant information on foreign search report			
	[insert necessary translation here]			
Other Info	rmation			
Payment of	of Fees Due (If Any):			
A check for \$ covering the fee identified above is attached.				
☐ Pa	Payment by credit card via EFS for \$ covering the fee identified above.			
☐ Ple	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.			

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit
Account #13-3402

Respectfully submitted,

/Csaba Henter/

Csaba Henter, Reg. No. 50,908 Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3073

Date: January 2, 2009

CH/pdr